MSN Labs enters into licensing agreement with Lilly
The drug baricitinib has been granted a restricted emergency use approval in India by the Central Drugs Standard Control Organization (CDSCO) for emergency use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19
Hyderabad: Hyderabad-based MSN Labs (MSN) entered into a royalty-free, non-exclusive, voluntary license agreement with Eli Lilly and Company of USA for manufacturing and marketing of baricitinib for Covid-19 in India.
The drug baricitinib has been granted a restricted emergency use approval in India by the Central Drugs Standard Control Organization (CDSCO) for emergency use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Dr MSN Reddy, CMD, MSN Group, commented “This collaboration with Eli Lilly and Company is a landmark milestone in India’s fight against Covid-19 and will thus help in increasing the availability and affordability of baricitinib”.
MSN will be launching the product under the brand name Baridoz in two strengths 2 mg and 4mg. The company has developed the active pharmaceutical ingredient and the formulation of baricitinib in its in-house R&D and manufacturing units.
As part of the Covid treatment range, MSN has already launched Favilow (Favipiravir) in the strengths of 200mg, 400mg & 800mg and Oselow (Oseltamivir) as 75 mg capsules.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
